Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stage II or III multiple myeloma according to Durie and Salmon criteria, patients older than 75 years, previously untreated patients.~Exclusion Criteria:~* Prior history of another neoplasm (except basocellular cutaneous or cervical epithelioma)~* Primary or associated amyloïdosis~* World Health organisation performance index of at least 3~* Significant renal insufficiency with creatinine serum levels of 5.0 mg per deciliter or more~* Cardiac or hepatic dysfunction~* Cerebral circulatory insufficiency~* Absolute contraindication to corticosteroids~* Peripheral neuropathy clinically significant~* History of venous thrombosis during the last 6 months~* HIV or hepatitis B or C positivity~* Patients who had geography, social, or psychological conditions which might prevent adequate follow-up.

- Gender: ALL
- Minimum Age: 75 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: PLACEBO_COMPARATOR): 12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus placebo 100mg/d continuously for 18 months
- B (Type: ACTIVE_COMPARATOR): 12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus thalidomide 100mg/d continuously for 18 months

Based on this trial design, predict the completion outcome and termination type (if applicable).